The study analyses, empirically, the efficiency of the Pharmaceutical sector in Nigeria. Employing a balanced panel of 20 pharmaceutical firms between 2012 and 2016, the paper uses a non-parametric technique (Data Envelopment Analysis) to analyze the firms' efficiency under the constant returns to scale (CRS) and variable returns to scale (VRS) assumptions. The results obtained shows inefficiency in the pharmaceutical sector as it operates under a decreasing return to scale. This calls for an appropriate policy mix to stimulate the efficiency of the pharmaceutical sector in Nigeria by enhancing research and development (R&D) as ell as regulations within the sector.
and vast natural resources, the country is still fraught with poverty, diseases and malnutrition (World Health Organisation, 2013) . The World Health Organisation (WHO) rated Nigeria's health sector 187th out of 191 members (WHO, 2000) . The poor rating of the sector is due to a lack of standard equipment for production and storage of pharmaceuticals. As such, only a few of the pharmaceutical firms in Nigeria have the capacity to participate in the supply of anti-malaria, anti-TB medicines, anti-retroviral and other pharmaceuticals in international tenders (Lead Capital Ltd, 2008) .
Efficiency in the pharmaceutical sector can be measured using: (i) allocative efficiency, (ii) X-efficiency, (iii) distributional efficiency and (iv) technical efficiency coefficients. There are abundant empirical studies on efficiency and its determinants in the pharmaceutical sector of developed economies (Praven and Tapan, 2005; Adhikari, 2005; Jiankang, 2014; Chadda, 2006; Gupta, 2007; Chaturvedi and Chataway, 2006) , but there exists a dearth of such studies for developing countries like Nigeria. The growth of the Nigerian Pharmaceutical industry has been featured in few empirical studies, but to the best of our knowledge, a comprehensive work on the efficiency of the industry in a multivariate framework has not been carried out. One of the recent works in this area is that of Wakeel and Ekundayo (2016) . Their emphasis however, was on the determinants of the performance of the pharmaceutical industry in Nigeria. This study aims to fill this gap by analyzing empirically, the efficiency of the Pharmaceutical sector in Nigeria using a non-parametric technique (Data Envelopment Analysis) for a balanced panel of 20 pharmaceutical firms between 2012 and 2016.
The remaining part of the paper is structured as follows; section 2 gives a review of related literature, section 3 provides the methodology; section 4 analyzes the results obtained; and section 5 concludes the study with policy recommendations.
Literature Review 2.1 Theoretical Literature
Efficiency can be gauged in relation to a comparison between observed and optimal values of its output and input in the production process. Among the various theories of efficiency, the structure conduct and performance (SCP) model stands out. According to Mari (2009) the SCP model deals with the organization and operation of the free enterprise sector. The framework was derived from taking a neoclassical analysis of markets. It is a combination of empirical studies of industrial experience and economic theories (Giroh, et al., 2010; Shaik, et al., 2009 ). There are two competing hypotheses in the SCP framework: the traditional "structure performance hypothesis" and "efficient structure hypothesis". While the structure performance hypothesis asserts that the degree of market concentration inversely relates to the degree of competition, both going in opposite directions making concentrated firms to earn higher profits, the efficiency structure hypothesis states that the performance of the firm is positively related to its efficiency.
The efficiency theory has been widely adopted in various empirical studies (Demsetz 1973; Berger, 1995; Howard and Pollock, 1999; Cockburn, 2004; Praveen and Tapan, 2005; Tung, et al., 2010; and Jiankang, 2014) . The efficiency hypothesis suggests that the efficiency of a firm dictates the nature of the relationship between the performance of the firm and its structure. Simply put, a firm is said to be highly efficient in relation to close competitors if it can maximize its profit while reducing its current cost structure and current plant size (or expanding its operations). The firm can also be said to be highly efficient if it can minimize its current cost structure. In this hypothesis, the X-efficiency argument holds that firms will have low cost in their production if they possess more productive technologies (Demsetz, 1973; Brozen, 1982; Gale and Branch 1982) . The scale efficiency side of the debate states that some firms may be more efficient even though they may have similar technologies and management techniques thus acquiring market shares.
Empirical Literature
The issue of efficiency has featured in a number of empirical studies (Ferreira, 2014; Lee, 2012; Park, 2012; Behname, 2012; Sahoo and Mishra, 2012; Mensi and Zouari, 2011; Giroh, et al, 2010; Shaik, et al, 2009 ). For instance, Ferreira (2014) examined the efficiency of the banking industry in the European Union (EU) in relation to market concentration. Mishra and Vikas (2010) , using a modified structure conduct and performance (SCP) model, explored 176 pharmaceutical firms and arrived at the conclusion that there is a bi-lateral relationship between performance and conduct variables in the selected firms. The findings of the study of Ferreira (2014) complemented that of Lee (2012) Though the study adopted efficient structure hypothesis, the findings corroborated some of the findings of previous studies on the subject area.
While the majority of literature that adopted SCP model is found in the developed economies and mostly in the banking sector of such countries (Ferreira, 2014; Behname, 2012; Sahoo and Mishra, 2012; Park, 2012; Lee, 2012; Mensi and Zouari, 2011; Maniatis, 2006) , few studies were conducted on pharmaceutical firms operating in developing economies (Vyas, et al. 2012; Mishra and Chandra, 2010; Mishra and Vikas, 2010; Zhang & Li, 2009 ). Ogaji et al (2014) showed that the capacity utilization of the Nigerian pharmaceutical industry increased steadily but marginally over the period of 1984 to 2014.Furthermore, Ugbam and Okoro (2017) asserted that larger firms are more efficient in the pharmaceutical industry in Nigeria. This implies that smaller firms faced with stiff competition from rival firms will eventually wind up (Olugbenga, 2010) .
Methodology

The Data Envelopment Analysis (DEA)
There exist numerous techniques (statistical and econometrical) adopted in both theoretical and empirical consideration of efficiency. However, in recent years, the Data Envelopment Analysis (DEA) has become more popular (Zhu, 2002) 
The Data Envelopment Analysis (DEA) method was proposed by Charnes et al., (1978) . Analytically, this methodology employs linear programming to generate an efficient frontier and related efficiency indicators within homogeneous production units. DEA is a nonparametric method which measures economic efficiency.
It is a linear programming model, assuming no random mistakes, used to measure technical efficiency. In relation to a firm, an efficient firm is one that produces a certain quantity of output given a stipulated quantity of inputs. It can also be expressed as the use of the same quantity or less inputs to produce a given amount of output compared to other firms in a given strata. This technique has been explored in many fields including environmental, financial, security, power, and administration (Kwon and Lee, 2015; Tao et al, 2013; Tsolas and Charles, 2015; Wanke and Barros, 2014; Aristovnik et al, 2014; Fang and Li, 2015; Du et al, 2014; Lozano, 2015; Azadeh et al, 2015; Omrani, et al, 2015) . The technique is used to evaluate performance across a set of homogeneous production units with multiple resources and products. From the foregoing, the Nigerian pharmaceutical industry constitutes the Decision-Making Units (DMUs), which can be treated as multiproduct firms that transform resources (inputs) into products (outputs). By adopting the DEA, we seek to find the DMUs that produce the highest output levels by using the lowest input levels. The desired efficiency level of 100% can only be achieved if none of the inputs or outputs can be improved without worsening some of its other inputs or outputs.
In the Charnes, Cooper and Rhodes (CCR) model proposed in 1978, there are n DMUs to be evaluated, and each DMUj (j = 1, . . . , n) has m inputs (resources) and s outputs (products), which are denoted with the vectors xj = (x1j, ..., xmj)T and yj = (y1j, ..., ysj)T , respectively. It should be noted that the focus here is that of measuring relative efficiency. DEA seeks to maximize the scalar measure of efficiency (e0) of the DM U 0, as shown below;
> 0 µ r , ω r ≥ 0(r = 1, ..., s and i = 1, ..., m)
where ω i and µ r represent i − th input and r − th output weights for DM U 0 .
The model above is designed to evaluate the relative performance of some decision making unit (DMU), designated as DM U 0 , based on observed performance of j = 1, 2, ..., n DMUs. A DMU is to be regarded as an entity responsible for converting inputs into outputs.
The y rj ; x ij > 0 in the model are constants which represent observed amounts of the r th output and the i th input of the j th decision making unit which can be referred to as DM U j in a collection of j = 1, ..., n entities which utilize these i = 1, ..., m inputs and produce these r = 1, ..., s outputs. The numerator of the above expression represents a set of desired outputs and the denominator represents a collection of resources used to obtain these outputs. The value h0 * obtained from this ratio satisfies 0 ≤ h0 * ≤ 1 and can be interpreted as an efficiency rating in which h0 * = 1 represents full efficiency and h0 * ≤ 1 means inefficiency is present. The sign ( * ) indicates an optimal value obtained from solving the model.
It is assumed that h0 * is invariant to the units of measure used for the input and output variables. It is also assumed that the data is non-negative and that each DMU has at least one positive input and output value.
In this regard, Scale Efficiency (SE) measures the impact of the operating scale on DMU productivity, and is defined as shown below:
Given the above equation, the technical efficiency of a DMU can never exceed its pure technical efficiency. In this way, the overall efficiency or technical efficiency (CCR) can be decomposed as follows:
The CCR model calculates the technical efficiency (TE), which measures the success of a DMU in producing as large outputs from a given set of inputs (Farrell, 1959) . Whereas the BCC model according to Kumar and Gulati (2008) , calculates the pure technical efficiency. it is assumed that the firms are operating at an optimal level, while in the VRS, the firm is assumed to be operating below optimal level.
As required by this study, we adopted the Malmquist Productivity Index (MPI) first introduced by Fare et al. (1994) , to evaluate the efficiency changes between two time periods. The index is given as:
0 is the Malmquist productivity index with output orientation, y represents the output vector that can be obtained with the resource vector x, and D 0 denotes the distance function. The MPI can be decomposed into technical efficiency changes and technological frontier changes, in the following way:
Where the first parenthesis measures technical efficiency change (TEC) between period t and t + 1, the geometric mean of the two ratios in the second parenthesis measures production frontier change (FC) between two time periods. From the foregoing, Malmquist index is expressed as:
relates to the level of effort that the DMU has been to achieve efficiency, and measures the capacity of the DMU to shift closer to or further away from the technological frontier from one time period to the next. Whereas, F C t,t+1 0 (technological change index) equals changes in the efficient frontier relative to the DMU in two time periods and is usually associated with capital investment and long-term planning strategies.
The DEA was adopted for the study since it does not require a priori assumption of functional specification relating inputs to outputs and does not demand for the distributional assumption of the error term.
Data and Variables
The population of the study constitutes the over 110 pharma-formulation manufac- Table 1 shows the descriptive statistics of the variables employed in the study. A critical view of the table shows that efficiency scores were calculated using one output variable and three input variables, and as specified in the model, there were six variables (independent) to measure how firm-specific factors impact on the efficiency of the employed pharmaceutical firms. The average age of pharmaceutical firms in Nigeria was observed to be about 13 years. The table showed that the Nigerian pharmaceutical sector exports about 26% of its produce. These exports are majorly to the ECOWAS countries. The financial strength of the pharmaceutical sector, as captured by the average leverage ratio, was approximately 3.7%. This is generally low, and it calls for more financing in this sector. The average market share from the table was 2% since the industry has many players. The average sales growth is approximately 10%. This calls for swift attention in the Nigerian pharmaceutical sector. The average values of the technical efficiency under CRS and VRS assumptions which are 0.64734 and 0.61034, respectively, shows that the pharmaceutical sector in Nigeria is relatively less efficient and shows that there is need to improve the sector.
Results and Discussion
Descriptive Results
Unit Root Test
The first econometric requirement for estimating a model is that the variables to be used must be stationary I(0) series. Before testing if the series follow a unit root, we checked the possibility of cross-sectional dependence in the series which will likely invalidate the unit root tests. The results obtained from the cross-sectional dependence (CD) test of Pesaran (2004) are shown below. Table 2 , the null hypothesis of no cross-sectional dependence can be strongly rejected given that the p-value = 0 for all the variables. In the light of this, we applied the cross-sectionally Augmented Dickey-Fuller (CADF) and cross-sectionally Im-Pesaran-Shin (CIPS) as proposed by Im, et al. (1995) and Harnsen (1995) , respectively. The results from these are presented below. 
Data Envelopment Analysis
Conclusion and Policy Implications
Performance analysis constitutes a major objective of any organization. Owing to this, the purpose of this study was to assess the efficiency of the pharmaceutical sector in Nigeria. Employing sales as output variable; cost of sales, operating expenses, and capital as input variables; and age of firm, exports performance, leverage, market share, firm size, and sales growth as independent variables, the study found oscillatory movements observed under the CRS and VRS assumptions from year-to-year. Scale efficiency change and technical efficiency change both experienced a decreasing return to scale indicating an urgent need to address the issue of efficiency in the pharmaceutical sector.
Given the low penetration of Nigerian pharmaceuticals in the global market, there is need to improve on the quality and standard of the pharmaceutical sector in Nigeria so as to meet up with internationally-accepted standards to facilitate participation and competition with countries such as China, India, Turkey and others. This is imperative given the negative coefficient of export performance under both the CRS and VRS assumptions. There is also need to increase financial support to the sector to aid with technological advancement. 
